Trial reportEuropean urology oncology2021
Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial.
Trial report in European urology oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01407263 (A Randomized Trial of Modifications to Radical Prostatectomy), which is not on this map. Cited by 81 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Trial of Modifications to Radical Prostatectomy
Who cites it
81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 169 citations in OpenAlex.
- Prognosis of radical prostatectomy combined with pelvic lymph node dissection in patients with intermediate- and high-risk prostate cancer: a systematic review and single-arm meta-analysis.International urology and nephrology · 2026Pooled it
- Different lymph node dissection ranges during radical prostatectomy for patients with prostate cancer: a systematic review and network meta-analysis.World journal of surgical oncology · 2023Pooled it
- Digital integration of research conduct into clinical care: results of the PROSPECTOR randomised feasibility study.BMJ evidence-based medicine · 2025Trial
- Impact of peritoneal bladder flap in robot-assisted radical prostatectomy patients on lymphoceles: a prospective randomised trial.World journal of urology · 2025Trial
- Randomized Trial of Transverse vs Vertical Extraction Site Incision After Robotic Radical Prostatectomy.The Journal of urology · 2024Trial
- Targeted pelvic lymph node dissection using magnetic resonance imaging - ultrasonography fusion technique and indocyanine green injection in robot-assisted radical prostatectomy.Journal of robotic surgery · 2026Article
- From reflex to reason: rethinking pelvic lymph node dissection in the PSMA PET Era.European journal of nuclear medicine and molecular imaging · 2026Article
- Global research trends in pelvic lymph node dissection during robot-assisted radical prostatectomy: a bibliometric and knowledge-mapping analysis.Journal of robotic surgery · 2026Article
- Pelvic lymph node dissection during robot-assisted radical prostatectomy: a bibliometric analysis of surgical extent, nodal staging, and lymphatic morbidity.Journal of robotic surgery · 2026Review
- Guideline of guidelines: pelvic lymph node dissection at time of radical prostatectomy.BJU international · 2026Review
- The utility of pelvic lymph node dissection in PSMA-PET negative intermediate and high-risk prostate cancer patients undergoing radical prostatectomy.World journal of urology · 2026Article
- The Lymphatic-Bone Axis in Cancer Metastasis.Cancers · 2026Review
- Multifocal cohort analysis unveils cell types associated with regional lymph node seeding in prostate cancer.Genome medicine · 2026Article
- Practice patterns of Urological Society of Australia and New Zealand urologists regarding pelvic lymph node dissection in prostate cancer surgery.Prostate international · 2026Article
- Extended versus limited pelvic lymph node dissection and long-term outcomes in high-risk prostate cancer before radiotherapy.BJUI compass · 2026Article
- PSMA PET/CT-guided pelvic lymph node dissection in patients with unfavorable intermediate- or high-risk prostate cancer.The Canadian journal of urology · 2026Article
- Report of the Advanced Prostate Cancer Consensus Conference-JAPAN 2025 at the 112Translational andrology and urology · 2026Article
- Prediction of Contralateral Lymph Node Involvement during Extended Pelvic Lymph Node Dissection for Clinically Unilateral Prostate Cancer.Annals of surgical oncology · 2026Article
- Impact of Negative Prostate-specific Membrane Antigen Positron Emission Tomography on the Decision to Perform a Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- to High-risk Prostate Cancer Patients: Results of an International Survey.European urology open science · 2026Article
- External Validation of Nomograms for Predicting Pelvic Lymph Node Metastases in Patients with Prostate Cancer and the Added Value of the Prostate-specific Membrane Antigen Positron Emission Tomography-based PRIMARY Score.European urology open science · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPelvic lymph node dissection (PLND) is the most reliable procedure for lymph node staging. However, the therapeutic benefit remains unproven; although most radical prostatectomies at academic centers are accompanied by PLND, there is no consensus regarding the optimal anatomical extent of PLND.
objectiveTo evaluate whether extended PLND results in a lower biochemical recurrence rate. DESIGN, SETTING, AND
participantsWe conducted a single-center randomized trial. Patients, enrolled between October 2011 and March 2017, were scheduled to undergo radical prostatectomy and PLND. Patients were assigned to limited or extended PLND by cluster randomization. Specifically, surgeons were randomized to perform limited or extended PLND for 3-mo periods.
interventionRandomization to limited (external iliac nodes) or extended (external iliac, obturator fossa and hypogastric nodes) PLND. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was the rate of biochemical recurrence. RESULTS AND LIMITATIONS: Of 1440 patients included in the final analysis, 700 were randomized to limited PLND and 740 to extended PLND. The median number of nodes retrieved was 12 (interquartile range [IQR] 8-17) for limited PLND and 14 (IQR 10-20) extended PLND; the corresponding rate of positive nodes was 12% and 14% (difference -1.9%, 95% confidence interval [CI] -5.4% to 1.5%; p = 0.3). With median follow-up of 3.1 yr, there was no significant difference in the rate of biochemical recurrence between the groups (hazard ratio 1.04, 95% CI 0.93-1.15; p = 0.5). Rates for grade 2 and 3 complications were similar at 7.3% for limited versus 6.4% for extended PLND; there were no grade 4 or 5 complications.
conclusionsExtended PLND did not improve freedom from biochemical recurrence over limited PLND for men with clinically localized prostate cancer. However, there were smaller than expected differences in nodal count and the rate of positive nodes between the two templates. A randomized trial comparing PLND to no node dissection is warranted. PATIENT SUMMARY: In this clinical trial we did not find a difference in the rate of biochemical recurrence of prostate cancer between limited and extended dissection of lymph nodes in the pelvis. This study is registered on ClinicalTrials.gov as NCT01407263.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.